ARTICLE | Company News
Palatin, AMAG deal
January 20, 2017 7:32 PM UTC
Palatin granted AMAG exclusive, North American rights to develop and commercialize Rekynda bremelanotide. Palatin will receive $60 million up front and is eligible for up to $80 million in regulatory ...
BCIQ Target Profiles